Alladapt Immunotherapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • Liquidation

Alladapt Immunotherapeutics General Information

Description

Developer of prescription therapeutics designed to target food allergies. The company's medication is being advanced as a broad-spectrum oral immunotherapy treatment to mitigate food allergies triggered by single or multiple proteins from an expansive set of common allergens, enabling doctors to effectively treat patients with various allergies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 405 El Camino Real
  • Suite 611
  • Menlo Park, CA 94025
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 405 El Camino Real
  • Suite 611
  • Menlo Park, CA 94025
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alladapt Immunotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 23-Jul-2024 Completed Bankruptcy: Liquidation
5. Debt - General 24-Aug-2022 Completed Generating Revenue
4. Later Stage VC (Series D) 05-May-2022 Completed Generating Revenue
3. Later Stage VC (Series C) 19-Feb-2020 Completed Generating Revenue
2. Early Stage VC (Series B) 20-Mar-2018 $1.1M $1.5M Completed Generating Revenue
1. Early Stage VC (Series A) $400K $400K Completed Startup
To view Alladapt Immunotherapeutics’s complete valuation and funding history, request access »

Alladapt Immunotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D-2
Series D-1
Series D
Series C
Series B 12,499,993 $0.000100 $0.01 $0.1 $0.1 1x $0.1 3.04%
Series A 9,365,072 $0.000100 $0 $0.05 $0.05 1x $0.05 2.28%
To view Alladapt Immunotherapeutics’s complete cap table history, request access »

Alladapt Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of prescription therapeutics designed to target food allergies. The company's medication is being advanced as
Drug Discovery
Menlo Park, CA
46 As of 2023

Chicago, IL
 

Berkeley, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alladapt Immunotherapeutics Competitors (23)

One of Alladapt Immunotherapeutics’s 23 competitors is ClostraBio, a Venture Capital-Backed company based in Chicago, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ClostraBio Venture Capital-Backed Chicago, IL
Actym Therapeutics Venture Capital-Backed Berkeley, CA
Elevar Therapeutics Formerly VC-backed Fort Lee, NJ
Immunomic Therapeutics Venture Capital-Backed Rockville, MD
Byondis Corporation Nijmegen, Netherlands
You’re viewing 5 of 23 competitors. Get the full list »

Alladapt Immunotherapeutics Patents

Alladapt Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024186702-A1 Methods of treating allergies Inactive 03-Mar-2023
US-20240133898-A1 Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies Inactive 24-Feb-2021
US-20240230671-A9 Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies Inactive 24-Feb-2021
WO-2022182872-A2 Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies Inactive 24-Feb-2021
WO-2022182872-A3 Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies Inactive 24-Feb-2021 G01N33/6854
To view Alladapt Immunotherapeutics’s complete patent history, request access »

Alladapt Immunotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alladapt Immunotherapeutics FAQs

  • When was Alladapt Immunotherapeutics founded?

    Alladapt Immunotherapeutics was founded in 2018.

  • Where is Alladapt Immunotherapeutics headquartered?

    Alladapt Immunotherapeutics is headquartered in Menlo Park, CA.

  • What is the size of Alladapt Immunotherapeutics?

    Alladapt Immunotherapeutics has 46 total employees.

  • What industry is Alladapt Immunotherapeutics in?

    Alladapt Immunotherapeutics’s primary industry is Drug Discovery.

  • Is Alladapt Immunotherapeutics a private or public company?

    Alladapt Immunotherapeutics is a Private company.

  • What is Alladapt Immunotherapeutics’s current revenue?

    The current revenue for Alladapt Immunotherapeutics is .

  • How much funding has Alladapt Immunotherapeutics raised over time?

    Alladapt Immunotherapeutics has raised $230M.

  • Who are Alladapt Immunotherapeutics’s competitors?

    ClostraBio, Actym Therapeutics, Elevar Therapeutics, Immunomic Therapeutics, and Byondis are some of the 23 competitors of Alladapt Immunotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process